IRAK-M Regulates Monocyte Trafficking to the Lungs in Response to Bleomycin Challenge.
Animals
Anti-Bacterial Agents
/ therapeutic use
Bleomycin
/ therapeutic use
Cell Movement
/ drug effects
Disease Models, Animal
Humans
Idiopathic Pulmonary Fibrosis
/ drug therapy
Interleukin-1 Receptor-Associated Kinases
/ genetics
Mice
Mice, Inbred C57BL
Mice, Knockout
Monocytes
/ drug effects
Receptors, CCR2
/ metabolism
Signal Transduction
Up-Regulation
Journal
Journal of immunology (Baltimore, Md. : 1950)
ISSN: 1550-6606
Titre abrégé: J Immunol
Pays: United States
ID NLM: 2985117R
Informations de publication
Date de publication:
15 05 2020
15 05 2020
Historique:
received:
23
04
2019
accepted:
16
03
2020
pubmed:
8
4
2020
medline:
20
2
2021
entrez:
8
4
2020
Statut:
ppublish
Résumé
Idiopathic pulmonary fibrosis is a deadly disease characterized by excessive extracellular matrix deposition in the lungs, resulting in decreased pulmonary function. Although epithelial cells and fibroblasts have long been the focus of idiopathic pulmonary fibrosis research, the role of various subpopulations of macrophages in promoting a fibrotic response is an emerging target. Healthy lungs are composed of two macrophage populations, tissue-resident alveolar macrophages and interstitial macrophages, which help to maintain homeostasis. After injury, tissue-resident alveolar macrophages are depleted, and monocytes from the bone marrow (BM) traffic to the lungs along a CCL2/CCR2 axis and differentiate into monocyte-derived alveolar macrophages (Mo-AMs), which is a cell population implicated in murine models of pulmonary fibrosis. In this study, we sought to determine how IL-1R-associated kinase-M (IRAK-M), a negative regulator of TLR signaling, modulates monocyte trafficking into the lungs in response to bleomycin. Our data indicate that after bleomycin challenge, mice lacking IRAK-M have decreased monocyte trafficking and reduced Mo-AMs in their lungs. Although IRAK-M expression did not regulate differences in chemokines, cytokines, or adhesion molecules associated with monocyte recruitment, IRAK-M was necessary for CCR2 upregulation following bleomycin challenge. This finding prompted us to develop a competitive BM chimera model, which demonstrated that expression of BM-derived IRAK-M was necessary for monocyte trafficking into the lung and for subsequent enhanced collagen deposition. These data indicate that IRAK-M regulates monocyte trafficking by increasing the expression of CCR2, resulting in enhanced monocyte translocation into the lung, Mo-AM differentiation, and development of pulmonary fibrosis.
Identifiants
pubmed: 32253243
pii: jimmunol.1900466
doi: 10.4049/jimmunol.1900466
pmc: PMC7356730
mid: NIHMS1598787
doi:
Substances chimiques
Anti-Bacterial Agents
0
Ccr2 protein, mouse
0
Receptors, CCR2
0
Bleomycin
11056-06-7
Interleukin-1 Receptor-Associated Kinases
EC 2.7.11.1
Irak3 protein, mouse
EC 2.7.11.1
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2661-2670Subventions
Organisme : NCI NIH HHS
ID : P30 CA016058
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL137224
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL141217
Pays : United States
Informations de copyright
Copyright © 2020 by The American Association of Immunologists, Inc.
Références
Nat Immunol. 2019 Feb;20(2):163-172
pubmed: 30643263
J Pathol. 2004 Dec;204(5):594-604
pubmed: 15538737
Nat Rev Immunol. 2011 Oct 10;11(11):762-74
pubmed: 21984070
J Immunol. 2006 Jun 15;176(12):7412-20
pubmed: 16751386
Mol Cell Neurosci. 2008 Jan;37(1):170-7
pubmed: 17949992
J Immunol. 2013 Apr 1;190(7):3447-57
pubmed: 23467934
J Immunol. 2001 Oct 15;167(8):4368-77
pubmed: 11591761
Am J Respir Crit Care Med. 2011 Sep 1;184(5):569-81
pubmed: 21680953
J Immunol. 2017 May 15;198(10):4074-4085
pubmed: 28373581
Mol Cell Biol. 2010 Nov;30(22):5381-93
pubmed: 20837707
Radiat Res. 2018 Mar;189(3):300-311
pubmed: 29332538
J Immunol. 2018 Jan 15;200(2):471-476
pubmed: 29246952
Am J Respir Cell Mol Biol. 2011 Oct;45(4):781-8
pubmed: 21330464
Science. 2009 Jul 31;325(5940):612-6
pubmed: 19644120
J Immunol. 2009 Aug 1;183(3):1900-10
pubmed: 19596996
JCI Insight. 2016 Oct 20;1(17):e88947
pubmed: 27777976
Am J Respir Cell Mol Biol. 2017 Sep;57(3):294-306
pubmed: 28421818
Cell Res. 2011 Jul;21(7):1068-79
pubmed: 21467996
J Exp Med. 2017 Aug 7;214(8):2387-2404
pubmed: 28694385
Eur J Immunol. 2018 Sep;48(9):1445-1455
pubmed: 29879295
J Immunol. 2012 Jul 1;189(1):356-64
pubmed: 22661086
Eur Respir J. 2016 Jul;48(1):179-86
pubmed: 27126689
Am J Respir Cell Mol Biol. 2014 May;50(5):848-52
pubmed: 24605795
Eur Respir Rev. 2015 Sep;24(137):505-9
pubmed: 26324812
J Pathol. 2017 Nov;243(3):320-330
pubmed: 28799208
J Clin Invest. 2006 Sep;116(9):2532-42
pubmed: 16917541
Front Med (Lausanne). 2018 Mar 20;5:43
pubmed: 29616220
Front Med. 2014 Dec 22;1(56):
pubmed: 25580363
J Immunol. 2003 Mar 15;170(6):3273-8
pubmed: 12626586
Lancet Respir Med. 2019 Jun;7(6):497-508
pubmed: 30935881
Nat Commun. 2018 Feb 14;9(1):676
pubmed: 29445158
J Immunol. 2005 Sep 15;175(6):3637-47
pubmed: 16148108
Am J Physiol Lung Cell Mol Physiol. 2003 Feb;284(2):L342-9
pubmed: 12388376
Am J Respir Cell Mol Biol. 1996 Apr;14(4):309-15
pubmed: 8600933
Am J Physiol Lung Cell Mol Physiol. 2016 Sep 1;311(3):L611-27
pubmed: 27448666
J Immunol. 2015 Feb 15;194(4):1894-904
pubmed: 25595781
Am J Respir Cell Mol Biol. 2018 Jan;58(1):66-78
pubmed: 28850249
Eur Respir J. 2015 Dec;46(6):1740-50
pubmed: 26493793
Exp Lung Res. 2008 Jun;34(5):263-75
pubmed: 18465404
Hepatology. 2018 Apr;67(4):1270-1283
pubmed: 28940700
J Mol Cell Biol. 2015 Dec;7(6):557-67
pubmed: 26101328
Am J Respir Cell Mol Biol. 2015 Jun;52(6):772-84
pubmed: 25360868
Am J Respir Cell Mol Biol. 2016 Jan;54(1):1-2
pubmed: 26720905
Am J Respir Crit Care Med. 2019 Jun 15;199(12):1517-1536
pubmed: 30554520
Biochem Biophys Res Commun. 2005 Jun 24;332(1):188-93
pubmed: 15896316
Sci Rep. 2015 Jul 24;5:11664
pubmed: 26206182